What is HC Wainwright’s Estimate for WVE FY2025 Earnings?

WAVE Life Sciences Ltd. (NASDAQ:WVE) – Equities research analysts at HC Wainwright lowered their FY2025 earnings estimates for WAVE Life Sciences in a report released on Tuesday, November 11th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($1.17) for the year, down from their previous estimate of ($0.97). HC Wainwright has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for WAVE Life Sciences’ current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for WAVE Life Sciences’ Q4 2025 earnings at ($0.27) EPS.

A number of other research firms also recently weighed in on WVE. Canaccord Genuity Group initiated coverage on shares of WAVE Life Sciences in a research report on Monday, August 4th. They set a “buy” rating and a $19.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of WAVE Life Sciences in a report on Wednesday, October 8th. Leerink Partners set a $26.00 target price on shares of WAVE Life Sciences in a research note on Wednesday, September 3rd. B. Riley reaffirmed a “buy” rating on shares of WAVE Life Sciences in a research report on Thursday, September 4th. Finally, Wedbush lifted their price target on WAVE Life Sciences from $18.00 to $20.00 and gave the stock an “outperform” rating in a research note on Tuesday. Eleven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, WAVE Life Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.73.

WAVE Life Sciences Stock Down 4.3%

WVE stock opened at $6.95 on Thursday. The stock’s 50 day moving average is $7.46 and its two-hundred day moving average is $7.56. WAVE Life Sciences has a 52-week low of $5.28 and a 52-week high of $16.71. The company has a market capitalization of $1.11 billion, a PE ratio of -7.72 and a beta of -1.44.

WAVE Life Sciences (NASDAQ:WVE) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). The business had revenue of $7.61 million during the quarter, compared to the consensus estimate of $9.85 million.

Insider Transactions at WAVE Life Sciences

In related news, CEO Paul Bolno sold 217,351 shares of WAVE Life Sciences stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $10.10, for a total value of $2,195,245.10. Following the sale, the chief executive officer directly owned 121,000 shares in the company, valued at $1,222,100. This trade represents a 64.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Gregory L. Verdine sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $10.00, for a total transaction of $100,000.00. Following the completion of the sale, the director owned 285,217 shares in the company, valued at $2,852,170. The trade was a 3.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 23.98% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of WVE. Bessemer Group Inc. raised its stake in shares of WAVE Life Sciences by 1,156.3% during the third quarter. Bessemer Group Inc. now owns 9,925 shares of the company’s stock valued at $72,000 after purchasing an additional 9,135 shares in the last quarter. Knott David M Jr acquired a new position in WAVE Life Sciences during the 1st quarter valued at about $81,000. Ascent Group LLC bought a new stake in shares of WAVE Life Sciences during the 1st quarter worth about $83,000. Verdence Capital Advisors LLC acquired a new stake in shares of WAVE Life Sciences in the 3rd quarter worth approximately $86,000. Finally, Ameritas Investment Partners Inc. lifted its stake in shares of WAVE Life Sciences by 18.7% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 11,444 shares of the company’s stock worth $74,000 after acquiring an additional 1,802 shares during the period. 89.73% of the stock is owned by institutional investors and hedge funds.

WAVE Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.